RESUMO
OBJECTIVE: To compare the effects of long-term lansoprazole and omeprazole treatment (6 months) on serum gastrin levels. PATIENTS: Forty duodenal ulcer patients without previous treatment with proton pump inhibitors were randomized to receive either 20 mg/day or omeprazole or 30 mg/day of lansoprazole. Serum gastrin levels were determined on entry and every 2 months. On finalizing the study antral and fundic biopsies were obtained for immunohistochemical analysis of the enterochromaffin-like cell population. RESULTS: Before starting the treatment fasting serum gastrin was similar in both groups (108.7 +/- 60.9 pg/mL omeprazole; 102.7 +/- 56.9 pg/mL lansoprazole). The treatment with either omeprazole or lansoprazole increased serum gastrin levels, but the increase was mild, maximal at 2 months and similar between omeprazole and lansoprazole (113.44 +/- 114.9 pg/mL omeprazole vs 166.1 +/- 117.9 pg/mL lansoprazole; p > 0.05). When serum gastrin levels were individually analyzed by patient, most were below 200 pg/mL and only 3 patients (1 omeprazole/2 lansoprazole) had levels near 500 pg/mL which were not correlated with enterochromaffin-like cell hyperplasia. CONCLUSIONS: Long-term treatment with either omeprazole or lansoprazole is safe, at least during 6 months, and results in mild hypergastrinemia. No differences between these two drugs were observed.
Assuntos
Antiulcerosos/efeitos adversos , Mucosa Gástrica/patologia , Gastrinas/sangue , Omeprazol/análogos & derivados , 2-Piridinilmetilsulfinilbenzimidazóis , Antiulcerosos/uso terapêutico , Método Duplo-Cego , Feminino , Humanos , Lansoprazol , Masculino , Pessoa de Meia-Idade , Omeprazol/efeitos adversos , Omeprazol/uso terapêutico , Úlcera Gástrica/tratamento farmacológico , Úlcera Gástrica/patologiaAssuntos
Bicarbonatos/metabolismo , Mucosa Gástrica/metabolismo , Muco/fisiologia , Animais , Duodenopatias/fisiopatologia , Mucosa Gástrica/efeitos dos fármacos , Infecções por Helicobacter/fisiopatologia , Helicobacter pylori , Humanos , Muco/química , Muco/efeitos dos fármacos , Gastropatias/fisiopatologiaRESUMO
La dispepsia funcional es una entidad de alta prevalencia (hasta 30 por ciento según las series), en la que desconocemos el origen de los síntomas y sus mecanismos adyacentes, lo que dificulta su individualización y, por consiguiente, su manejo diagnóstico y terapéutico. Rara vez constituye un problema que el médico considere grave, pero el impacto sobre el enfermo es a menudo muy importante porque aminoran su calidad de vida e induce un alto índice de frecuentación, sobre todo de las consultas de medicina general (AU)